Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, Imamura M,
Keywords: Streptozocin, pNETs,
Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Toriyama K, Hijioka S, Komoto I, Kobayashi N, Okusaka T,
Introduction: Recent studies have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Hijioka S
Authors: Hijioka S, Hosoda W, Matsuo k, Ueno M, Furukawa M,
Introduction: Recent studies have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Hijioka S
Authors: Hijioka S,
Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,
Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,